Literature DB >> 9823985

Lung cancer--management and outcome in Glasgow, 1991-92.

E Kesson1, C E Bucknall, L G McAlpine, R Milroy, D Hole, D R Vernon, F Macbeth, C R Gillis.   

Abstract

Current practice and outcome for patients with lung cancer were determined by retrospective case note review of a random sample of all lung cancer cases registered for a calendar year and augmented by review of all surgical and radical radiotherapy cases. A total of 262 patients - 231 patients less than 75 years of age and 31 patients more than 75 years of age - represented 83% of the random sample. Eighty-three per cent of patients were seen within 2 weeks of referral. One-third reported symptoms occurring for less than 1 month and one-third had experienced symptoms for more than 3 months. The median time interval from first hospital contact until the making of a management decision was 18 days. The median interval from first contact to surgery was 63 days, and to starting radical radiotherapy 70 days. Histological confirmation was obtained in 69% of patients. Ten per cent of all lung cancer patients were calculated to have received chemotherapy. Five per cent of the whole cohort had definitive surgery and 64% of these were judged to be free of the disease at 3 years. Overall survival was 9% at 3 years, with no differences relating to cell type or area of residence. Many areas of good practice have been identified, but the lack of tumour staging or performance status data, the low proportion receiving chemotherapy or definitive surgery and the poor outcome after radical radiotherapy indicate the need for prospective audit and feedback of results. The long time interval from management decision to surgery and radiotherapy suggests organizational issues which need attention.

Entities:  

Mesh:

Year:  1998        PMID: 9823985      PMCID: PMC2063194          DOI: 10.1038/bjc.1998.690

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  6 in total

1.  Age and the treatment of lung cancer.

Authors:  J S Brown; D Eraut; C Trask; A G Davison
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

2.  Management of lung cancer in South East Scotland.

Authors:  R J Fergusson; A Gregor; R Dodds; G Kerr
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

Review 3.  Management of lung cancer.

Authors:  M F Muers; R A Haward
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

4.  Investigation, treatment and prognosis of bronchial carcinoma in the Yorkshire Region of England 1976-1983.

Authors:  C K Connolly; W G Jones; J Thorogood; C Head; M F Muers
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

5.  Management of ovarian cancer: referral to a multidisciplinary team matters.

Authors:  E J Junor; D J Hole; C R Gillis
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

6.  Time trends in the outcome of lung cancer management: a study of 9,090 cases diagnosed in the Mersey Region, 1974-86.

Authors:  S W Watkin; G K Hayhurst; J A Green
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

  6 in total
  9 in total

1.  A population-based study of gefitinib in patients with non-small cell lung cancer.

Authors:  Kenji Hayashibara; Hiroaki Satoh; Yoko Shinohara; Masaharu Inagaki; Takayuki Kaburagi; Toshio Hashimoto; Koichi Kurishima; Hiroichi Ishikawa; Hideo Ichimura; Takeshi Nawa; Yasunori Funayama; Takeshi Matsumura; Katsunori Kagohashi; Takeshi Endo; Kinya Furukawa; Koji Kishi; Masaaki Sumi; Koichi Kamiyama; Shigemi Ishikawa
Journal:  Med Oncol       Date:  2008-10-31       Impact factor: 3.064

2.  Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study.

Authors:  A Gregor; C S Thomson; D H Brewster; P L Stroner; J Davidson; R J Fergusson; R Milroy
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

3.  Lung cancer patterns of care in south western Sydney, Australia.

Authors:  S K Vinod; G P Delaney; A E Bauman; M B Barton
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

4.  Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.

Authors:  Hiroyuki Nakamura; Hiroaki Satoh; Takayuki Kaburagi; Yoshihiro Nishimura; Yoko Shinohara; Masaharu Inagaki; Takeo Endo; Takefumi Saito; Kenji Hayashihara; Nobuyuki Hizawa; Koichi Kurishima; Takeshi Nawa; Katsunori Kagohashi; Koji Kishi; Hiroichi Ishikawa; Hideo Ichimura; Toshio Hashimoto; Yukio Sato; Mitsuaki Sakai; Koichi Kamiyama; Takeshi Matsumura; Koji Unoura; Kinya Furukawa
Journal:  Med Oncol       Date:  2012-11-02       Impact factor: 3.064

5.  Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  David E Ost; Sai-Ching Jim Yeung; Lynn T Tanoue; Michael K Gould
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

6.  Initial medical attention on patients with early-stage non-small cell lung cancer.

Authors:  Xing Chen; Ivan P Gorlov; Jun Ying; Kelly W Merriman; Marek Kimmel; Charles Lu; Cielito C Reyes-Gibby; Olga Y Gorlova
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

7.  Geographical inequalities in lung cancer management and survival in South East England: evidence of variation in access to oncology services?

Authors:  R H Jack; M C Gulliford; J Ferguson; H Møller
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

8.  Lung cancer referral patterns in the former Yorkshire region of the UK.

Authors:  P P Melling; A C Hatfield; M F Muers; M D Peake; C J Storer; C E Round; R A Haward; S M Crawford
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

9.  Survival from lung cancer in England and Wales up to 2001.

Authors:  Y K Zee; T Eisen
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.